PrEP News & Updates — what's changing in HIV prevention
PrEP is moving fast — new medicines, new dosing, new guidance. We track the developments that matter and explain what they mean for you. This page is reviewed and updated as PrEP evolves.
Curated by the Prepmedication.com Medical Review TeamLast updated 17 July 2026 · We add developments as official guidance and approvals change · How we review →
What the labels mean:Approval a new medicine or option cleared by regulators (e.g. FDA)Guidance new clinical guidance / recommendation (CDC · WHO · USPSTF)Access availability, cost & insurance coverage
Jul 2026
this month
Guidance
New tools added: drug-interaction checker now covers 112 medicines
Our free PrEP drug-interaction checker now spans 112 medicines, supplements and recreational drugs — each showing whether it's safe, needs monitoring, or is prohibited with Truvada, Descovy and Apretude, with the mechanism explained.
Why it matters: interactions are one of the most common PrEP questions, and a few enzyme-inducing drugs can make PrEP fail. Check yours before starting anything new.
Twice-a-year PrEP: FDA approves lenacapavir (Yeztugo)
Lenacapavir, a long-acting capsid inhibitor given as an injection just twice a year, was approved by the FDA in 2025 for HIV pre-exposure prophylaxis — the longest-acting PrEP yet. The PURPOSE trials showed near-100% protection, including in cisgender women.
Why it matters: two visits a year removes the daily-pill burden that trips up adherence. See where it fits in our comparison and options guide.
The World Health Organization recommended twice-yearly lenacapavir as an additional PrEP option, urging countries to roll it out — a major step for global access to long-acting prevention.
Why it matters: WHO backing accelerates availability and pricing negotiations, especially in high-burden regions. See how lenacapavir compares in our PrEP comparison.
The CDC published guidance on Doxy-PEP — a single 200 mg dose of doxycycline within 72 hours after sex to lower the risk of bacterial STIs (syphilis, chlamydia and, in some settings, gonorrhoea) for gay/bisexual men and transgender women.
Why it matters: PrEP prevents HIV but not other STIs. Doxy-PEP is a new layer of protection — details on our Doxy-PEP section.
USPSTF "Grade A" — PrEP must be covered with no cost-sharing (US)
The US Preventive Services Task Force gave PrEP its top "A" rating, meaning most insurers and Medicaid must cover the medication and its follow-up visits and labs with no out-of-pocket cost.
Why it matters: cost is the barrier people fear most — often it's $0. See how to get PrEP and pay little or nothing.
Apretude (cabotegravir): the first injectable PrEP
Apretude became the first long-acting injectable PrEP — an injection every 2 months instead of a daily pill — approved for all populations at risk, including cisgender women.
Why it matters: it opened the era of injectable prevention. Read the full Apretude guide.
📌 Staying current: we review this page against CDC, WHO, USPSTF and FDA updates and add new entries as guidance changes — so the information you rely on reflects the latest science. See our editorial & review policy.
Medical disclaimer. This page is general information, not medical advice. Approvals and guidance vary by country and change over time; confirm current details with a qualified clinician. If you may have been exposed to HIV in the last 72 hours, see PEP now.